ストックスクリーナーアプリを入手
12.05
1.55%
-0.19
前日終値:
$12.24
開ける：
$12.33
24時間の取引高:
733.23K
Relative Volume:
0.97
時価総額：
$778.30M
収益：
$202.09M
当期純損益:
$-61.69M
株価収益率:
-11.16
EPS:
-1.08
ネットキャッシュフロー:
$-35.64M
1週間 パフォーマンス:
-7.52%
1か月 パフォーマンス:
-14.30%
6か月 パフォーマンス:
-24.45%
1年 パフォーマンス:
-13.93%
1日の値動き範囲:
$11.59
$12.33
1週間の範囲:
$11.59
$13.18
52週間の値動き範囲:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
EOLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
12.05 | 778.30M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com Australia
Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com India
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace
Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus.com
Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - StockTitan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 - BioSpace
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Finance
Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - Marketscreener.com
Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia
Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - StockTitan
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire
Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa
Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com
Evolus executive Avelar Rui sells $369,867 in stock - Investing.com India
Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India
When the Price of (EOLS) Talks, People Listen - Stock Traders Daily
Evolus Executives Sell Shares to Cover Tax Obligations - TradingView
Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St
Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire
Evolus director Parschauer sells $167,465 in common stock - Investing.com India
Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com South Africa
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa
Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool
What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World
(EOLS) Investment Analysis - Stock Traders Daily
Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN
Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World
Evolus, Inc. to Host Earnings Call - ACCESS Newswire
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks
HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World
Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks
Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks
Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com
Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize
Assessing Evolus: Insights From 6 Financial Analysts - Benzinga
Evolus price target raised to $25 from $22 at Barclays - TipRanks
Evolus reports Q4 EPS (11c) vs (21c) last year - TipRanks
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
Evolus Inc (EOLS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Avelar Rui | See Remarks |
Mar 18 '25 |
Sale |
13.26 |
27,904 |
369,868 |
362,467 |
| Beaver Sandra | Chief Financial Officer |
Mar 18 '25 |
Sale |
13.26 |
8,996 |
119,243 |
173,583 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Mar 18 '25 |
Sale |
13.26 |
4,536 |
60,125 |
95,671 |
| MOATAZEDI DAVID | See Remarks |
Mar 18 '25 |
Sale |
13.26 |
103,376 |
1,370,249 |
514,870 |
| Parschauer Karah Herdman | Director |
Mar 12 '25 |
Sale |
12.99 |
12,888 |
167,465 |
32,183 |
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):